×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SPRY – ars pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SPRY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/10
08:00 am
spry
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
Low
Report
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
2/2
08:00 am
spry
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing =15 kg to <30 kg
Low
Report
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing =15 kg to <30 kg
1/29
07:41 am
spry
ARS Pharmaceuticals (NASDAQ:SPRY) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
ARS Pharmaceuticals (NASDAQ:SPRY) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/23
05:06 am
spry
ARS Pharmaceuticals (NASDAQ:SPRY) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
ARS Pharmaceuticals (NASDAQ:SPRY) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
1/21
10:32 am
spry
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use [Yahoo! Finance]
Low
Report
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use [Yahoo! Finance]
1/21
08:00 am
spry
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
Low
Report
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
1/9
12:22 pm
spry
ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating [Yahoo! Finance]
Low
Report
ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating [Yahoo! Finance]
12/30
08:12 am
spry
ARS Pharmaceuticals announces NMPA approval for neffy 2 mg [Yahoo! Finance]
Low
Report
ARS Pharmaceuticals announces NMPA approval for neffy 2 mg [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/10/2025
06:00 am
SPRY
ars pharmaceuticals, inc.
MISS
Report
-1.1%
ars pharmaceuticals, inc.
8/13/2025
07:00 am
SPRY
ars pharmaceuticals, inc.
MISS
Report
-9.9%
ars pharmaceuticals, inc.
5/14/2025
07:00 am
SPRY
ars pharmaceuticals, inc.
IN-LINE
Report
-9.8%
ars pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/21
12:32 pm
spry
Form SCHEDULE 13G ARS Pharmaceuticals, Filed by: BlackRock, Inc.
Medium
Report
Form SCHEDULE 13G ARS Pharmaceuticals, Filed by: BlackRock, Inc.
1/5
04:28 pm
spry
Form 4 ARS Pharmaceuticals, For: Jan 02 Filed by: Scott Kathleen D.
Low
Report
Form 4 ARS Pharmaceuticals, For: Jan 02 Filed by: Scott Kathleen D.
1/5
04:27 pm
spry
Form 4 ARS Pharmaceuticals, For: Jan 02 Filed by: Karas Eric
Low
Report
Form 4 ARS Pharmaceuticals, For: Jan 02 Filed by: Karas Eric
1/5
04:25 pm
spry
Form 4 ARS Pharmaceuticals, For: Jan 02 Filed by: Fitzpatrick Alexander A
Low
Report
Form 4 ARS Pharmaceuticals, For: Jan 02 Filed by: Fitzpatrick Alexander A
1/5
04:23 pm
spry
Form 4 ARS Pharmaceuticals, For: Jan 02 Filed by: Dorsey Brian
Low
Report
Form 4 ARS Pharmaceuticals, For: Jan 02 Filed by: Dorsey Brian
1/5
04:22 pm
spry
Form 4 ARS Pharmaceuticals, For: Jan 02 Filed by: Chakma Justin
Low
Report
Form 4 ARS Pharmaceuticals, For: Jan 02 Filed by: Chakma Justin
1/5
04:21 pm
spry
Form 4 ARS Pharmaceuticals, For: Jan 02 Filed by: Tanimoto Sarina
Low
Report
Form 4 ARS Pharmaceuticals, For: Jan 02 Filed by: Tanimoto Sarina
1/5
04:19 pm
spry
Form 4 ARS Pharmaceuticals, For: Jan 02 Filed by: Lowenthal Richard E
Low
Report
Form 4 ARS Pharmaceuticals, For: Jan 02 Filed by: Lowenthal Richard E
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: